Vaccinex Reports 2025 Annual Financial Results
Rhea-AI Summary
Vaccinex (OTCMKTS: VCNX) reported it released its 2025 annual financial results for the year ended December 31, 2025 and posted the financial statements on its website on April 29, 2026. The company is a clinical-stage developer of investigational antibody therapies for Alzheimer’s, Huntington’s, and cancer.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VCNX
On the day this news was published, VCNX gained 28.70%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VCNX fell 14.62% while peers were mixed: AXIM and AGNPF declined, but GRTX, OCEA, and ADXS rose, suggesting a stock-specific move rather than a broad biotech swing.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Q3 2024 earnings | Negative | -1.6% | Reported Q3 loss, low cash, financing steps, and Nasdaq compliance issues. |
| May 15 | Q1 2024 earnings | Negative | -1.6% | Q1 financials, reduced R&D and net loss amid Nasdaq non-compliance notice. |
Earnings updates have historically led to modest share price declines, indicating a pattern of slightly negative reactions to financial disclosures.
Over the past year, Vaccinex has repeatedly combined financial updates with progress in its Alzheimer’s program. Q1 and Q3 2024 earnings releases highlighted SIGNAL-AD data, small cash balances, net losses, and Nasdaq listing compliance challenges, with stock moves around -1.6%. A December 2025 financing agreement supported a Phase 2b Alzheimer’s trial. Today’s annual 2025 results continue this theme of funding clinical development alongside ongoing financial pressures.
Historical Comparison
Past earnings headlines for VCNX led to average moves of about -1.58%. The current pre-news decline of -14.62% substantially exceeds typical reactions to similar financial updates.
Earnings releases have repeatedly paired ongoing Alzheimer’s program updates with tight cash, net losses, and exchange listing compliance efforts.
Market Pulse Summary
The stock surged +28.7% in the session following this news. A strong positive reaction aligns with prior interest around Vaccinex’s Alzheimer’s and Huntington’s programs, but would exceed the typical -1.58% average move seen after past earnings. Investors previously focused on cash levels, net losses, and listing compliance. Any outsized upside could face risks if financial pressures persist or if expectations for future financings and trial milestones are not met in subsequent disclosures.
Key Terms
alzheimer’s medical
AI-generated analysis. Not financial advice.
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in Alzheimer’s disease. Vaccinex is based in Rochester, New York.
Investor Contact
Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 271-2700
eevans@vaccinex.com
